Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals — Investor Presentation (May 2020)

33 slides from Marinus Pharmaceuticals's investor presentation, May 4, 2020

  1. Slide 1: Corporate Overview 2020

    NASDAQ: MRNS @ MarinusPharma Corporate Overview 2020

  2. Slide 2: Safe Harbor Statement

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they ar e forward - looking statements reflecting the current beliefs and expectations of management mad

  3. Slide 3: Ganaxolone Targets Synaptic & Extrasynaptic GABA A Receptors

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone (GNX) Targets Synaptic & Extrasynaptic GABA A Receptors 3 Ganaxolone a positive allosteric GABA A modulator with a well - defined MOA designed to treat patients suffering from epilepsy and neuropsychiatric disorders. GNX is designed to

  4. Slide 4: Ganaxolone Development Pipeline

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I GANAXOLONE PHASE 1 PHASE 2 PHASE 3 ANTICIPATED MILESTONES Seizure Disorders Initiate mid - 2020 Data Q3 2020 Initiate 1H 2020 Data 2021 Depressive Disorders* Ganaxolone Development Pipeline Treatment Resistant Depression (TRD) Status Epilepticus (

  5. Slide 5: Status Epilepticus Indication

    Status Epilepticus Indication

  6. Slide 6: Status Epilepticus: Definition and Epidemiology

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Status Epilepticus (SE): Definition and Epidemiology Background • Continuous seizures lasting >5 min • Heterogenous patient population with various etiologies, including glioblastoma, vascular disease, encephalitis, drug or alcohol withdrawal or o

  7. Slide 7: Goals of a New Therapy for the Treatment of SE

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Goals of a new treatment Rapid cessation Maintenance of seizure control Prevent progression to IV anesthetics Goals of a New Therapy for the Treatment of SE 7 Benzodiazepine Administered Medically induced Coma Established Status Epilepticus (ESE)

  8. Slide 8: SE Trial Design

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Treatment Period Loading Dose Maintenance Taper Phase 2 SE Trial Design 8 Diagnosis of convulsive or non - convulsive SE Failed at least one 2 nd line IV AED but had not progressed to 3 rd line IV anesthetics Bolus plus continuous infusion 2 - 4 d

  9. Slide 9: Baseline Characteristics

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Baseline Characteristics 9 Data presented at AES 2019 NCSE: Non - convulsive status epilepticus; CSE: Convulsive status epilepticus; LAC: Lacosamide ; LEV: Levetiracetam • 8 males, 9 females • Mean age: 57 years old (range: 23 - 88) • 5 (29%) CSE,

  10. Slide 10: Phase 2 Trial Results Showed Rapid Onset, Durability of Efficacy at High Dose

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Phase 2 Trial Results Showed Rapid Onset, Durability of Efficacy at High Dose Cohort No escalation to IV anesthetics within 24 hrs from infusion initiation (Primary Endpoint) Status - free through 24 hrs from infusion initiation No escalation to a

  11. Slide 11: PK/PD Relationship and Rationale for Target Dose

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I PK/PD Relationship and Rationale for Target Dose 11 Seizure Burden Reduction Occurred Rapidly in All Dose Groups Modeled PK Curves for All Dose Groups High Dose Achieves Target Range ≥ 500 ng/mL for ~8 hours Only High Dose Provided Sustained Reduc

  12. Slide 12: IV Ganaxolone Safety Summary

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I IV Ganaxolone Safety Summary 12 Intubation: 9 patients were not intubated upon enrollment. Of these, 6 remained intubation - free during the entire ganaxolone treatment perio d Data presented at AES 2019 AE: adverse event / SAE: serious adverse ev

  13. Slide 13: Phase 3 SE Plan

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 SE Plan 13 • Target dose range extends GNX exposure ≥ 500 ng/mL to 12 hours; IV bolus followed by 36 - hour infusion followed by a 12 - hour taper (48 hours in total) • SE cessation within 30 minutes, No progression to IV anesthesia for at

  14. Slide 14: SE Phase 3 Clinical Planning: On Track for First Patient In September

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I SE Phase 3 Clinical Planning: On Track for First Patient In September 14 • 1:1 randomized, double - blind, placebo - controlled trial • Failure of a benzodiazepine and 2 second - line IV AEDs • 3 - minute bolus, 36 - hr infusion, 12 - hr taper • A

  15. Slide 15: CDKL5 Deficiency Disorder

    CDKL5 Deficiency Disorder

  16. Slide 16: CDKL5 Deficiency Disorder – Rare, Serious Epileptic Condition

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Cause Mutation of the cyclin - dependent kinase - like 5 (CDKL5) gene, located on the X chromosome Symptoms Early - onset, treatment refractory seizures, & severe neuro - developmental delay Most can’t walk, talk or care for themselves Suffer from

  17. Slide 17: CDD Phase 2 Trial Design

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I 26 weeks ganaxolone 600 mg 3x/day maximum 12 weeks Trial Details 2 sites in US; 1 site in Italy 6 females, 1 male – ages 2 - 16 Confirmed CDKL5 mutation, stable background treatment, >4 seizures per 28 - day period in baseline Baseline Characteris

  18. Slide 18: Efficacy & Safety Data in Phase 2 Trial in CDD

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Efficacy & Safety Data in Phase 2 Trial in CDD Data presented at AES 2018 18 • Patients experienced a median ‘minimally improved’ rating on CGI - I scale (Clinician rated) correlated with % change in seizure frequency • GNX was generally safe and

  19. Slide 19: Durable Responses Seen in CDD Phase 2 Extension

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Durable Responses Seen out to 18 Months in CDD Phase 2 Extension • 4 of 7 patients entered the extension period • Ganaxolone demonstrated preliminary evidence of sustained, long - term (out to 18 months) efficacy in a small cohort of CDD patients

  20. Slide 20: Global Phase 3 Pivotal Trial Design

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Global Phase 3 Pivotal Trial Design 20 Baseline 6 weeks Historical Control 8 weeks Double - Blind Phase Open - Label Phase Maintenance 13 weeks Titration 4 weeks Titration 4 weeks Open - Label Phase Trial Details • Evaluate the use of oral ganaxol

  21. Slide 21: Tuberous Sclerosis Complex

    Tuberous Sclerosis Complex

  22. Slide 22: Allo-S as Potential Biomarker Across Various Genetic Epilepsies

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Allo - S as Potential Biomarker Across Various Genetic Epilepsies 22 Scientific literature associates genetic orphan epilepsies with neurosteroid imbalances Marinus has identified abnormal neurosteroid levels in several patient subtypes These find

  23. Slide 23: Tuberous Sclerosis Complex – Rare, Serious Genetic Disorder

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Cause Defect or mutation of TSC1 and/or TSC2 genes Symptoms Benign tumors, seizures, cognitive impairment, behavioral problems, skin abnormalities Prevalence ~25K-40K refractory TSC patients in the U.S.* Treatments Limited approved treatments Mech

  24. Slide 24: Unmet Need in TSC Epilepsy and Scientific Rationale for Ganaxolone

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Unmet Need in TSC Epilepsy and Scientific Rationale for Ganaxolone • Epilepsy present in ~90% of individuals affected with TSC • Existing treatments fail to control seizures in ~60% of individuals with TSC - associated epilepsy • Uncontrolled seiz

  25. Slide 25: TSC Phase 2 Open-Label Clinical Trial Design

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I PART A PART B Base (4 Weeks) GNX Titration (4 Weeks) GNX Maintenance (8 Weeks) Open - Label Extension (OLE) (24 Weeks) * Available to patients that respond to GNX as defined per protocol TSC - Phase 2 Open - Label Clinical Trial Design • n = 30 •

  26. Slide 26: PCDH19 Related Epilepsy

    PCDH19 Related Epilepsy

  27. Slide 27: PCDH19-Related Epilepsy – Rare, Serious Epileptic Condition

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Cause Inherited mutation of protocadherin 19 (PCDH19) gene. Located on X chromosome Symptoms Early - onset seizures, cognitive and sensory impairment, & psychiatric and behavioral disorders. Seizures last from days to weeks; sensitive to fever Pre

  28. Slide 28: Seizure Reduction in PCDH19-RE Phase 2 Trial in Patients with Low Allo Levels

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Seizure Reduction in PCDH19 - RE Phase 2 Trial in Patients with Low Allo Levels • 25% decrease in median seizure frequency reported in Phase 2 (n=11) • Stratification of patients by baseline plasma Allo levels identifies a subpopulation with expec

  29. Slide 29: Biomarker Stratified Proof of Concept Study in PCDH19

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Biomarker Stratified Proof of Concept (POC) Study in PCDH19 29 Trial Details • Ages 1 - 17 with 8 or more seizures in 8 weeks, failed 2 or more AEDs • Expect to complete double - blind portion of the trial with ~15 - 20 patients • Stratify patient

  30. Slide 30: Intellectual Property

    Intellectual Property

  31. Slide 31: Multiple Layers Of Potential Protection

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Patent Expected Patent Life Synthesis patents issued in US, Australia, China, Europe, Japan, Mexico & New Zealand 2030 IV formulations containing exclusively in - licensed proprietary Captisol ® product 2033 SE – pending patent on IV formulations

  32. Slide 32: Thank You

    Thank You

  33. Slide 33: Appendix: Details on Baseline Characteristics for SE Patients

    ©2020 Marinus Pharmaceuticals. All Rights Reserved I Appendix 33 NCSE: Non - convulsive status epilepticus CSE: Convulsive status epilepticus LAC: Lacosamide LEV: Levetiracetam LOR: Lorazepam PHT: Phenytoin fPHT : Fosphenytoin VPA: Valproic Acid Details on Baseline Characteristics for SE Patients *B

Marinus Pharmaceuticals — Investor Presentation (May 2020) on 6ix